share_log

Allarity Therapeutics | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

Allarity Therapeutics | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

Allarity Therapeutics | S-1/A：證券上市註冊聲明(修正)
美股sec公告 ·  04/17 21:19
牛牛AI助理已提取核心訊息
Allarity Therapeutics, Inc. (ALLR.US), a clinical-stage biopharmaceutical company, has filed an amendment with the Securities and Exchange Commission (SEC) on April 17, 2024, for a registration statement related to the issuance of 5,000,000 shares of common stock. The company's shares are listed on Nasdaq under the symbol 'ALLR.' The registration statement includes a prospectus that provides detailed information about the offering, the company's business, financial statements, and the risks involved in investing in the company. The offering is subject to various terms and conditions, including the approval of legal matters by the underwriters' counsel and other customary closing conditions. The underwriters have the option to purchase additional shares to cover over-allotments. The proceeds from the offering are intended...Show More
Allarity Therapeutics, Inc. (ALLR.US), a clinical-stage biopharmaceutical company, has filed an amendment with the Securities and Exchange Commission (SEC) on April 17, 2024, for a registration statement related to the issuance of 5,000,000 shares of common stock. The company's shares are listed on Nasdaq under the symbol 'ALLR.' The registration statement includes a prospectus that provides detailed information about the offering, the company's business, financial statements, and the risks involved in investing in the company. The offering is subject to various terms and conditions, including the approval of legal matters by the underwriters' counsel and other customary closing conditions. The underwriters have the option to purchase additional shares to cover over-allotments. The proceeds from the offering are intended for general corporate purposes, including clinical trials, working capital, and other business needs. The company has also entered into agreements with the underwriters regarding the offering price, underwriting discounts, and indemnification provisions. The filing follows a series of financial activities by Allarity Therapeutics, including previous securities offerings and agreements with investors such as 3i, LP.
處於臨床階段的生物製藥公司Allarity Therapeutics, Inc.（ALLR.US）已於2024年4月17日向美國證券交易委員會（SEC）提交了與發行500萬股普通股相關的註冊聲明修正案。該公司的股票在納斯達克上市，股票代碼爲 “ALLR”。註冊聲明包括一份招股說明書，其中提供了有關本次發行、公司業務、財務報表以及投資公司所涉及風險的詳細信息。本次發行受各種條款和條件的約束，包括承銷商律師對法律事務的批准以及其他慣例成交條件。承銷商可以選擇購買額外股票以彌補超額配股。此次發行的收益用於一般公司用途，包括臨床試驗、營運資金和其他業務需求。該公司還與承銷商就發行價格、承保折扣和賠償條款簽訂了協議。該文件是在Allarity Therapeutics進行了一系列財務活動之後提交的，包括先前的證券發行以及與3i、LP等投資者達成的協議。
處於臨床階段的生物製藥公司Allarity Therapeutics, Inc.（ALLR.US）已於2024年4月17日向美國證券交易委員會（SEC）提交了與發行500萬股普通股相關的註冊聲明修正案。該公司的股票在納斯達克上市，股票代碼爲 “ALLR”。註冊聲明包括一份招股說明書，其中提供了有關本次發行、公司業務、財務報表以及投資公司所涉及風險的詳細信息。本次發行受各種條款和條件的約束，包括承銷商律師對法律事務的批准以及其他慣例成交條件。承銷商可以選擇購買額外股票以彌補超額配股。此次發行的收益用於一般公司用途，包括臨床試驗、營運資金和其他業務需求。該公司還與承銷商就發行價格、承保折扣和賠償條款簽訂了協議。該文件是在Allarity Therapeutics進行了一系列財務活動之後提交的，包括先前的證券發行以及與3i、LP等投資者達成的協議。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。